Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT07219420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Recruiting
Start date
November 14, 2025
Completion date
November 22, 2029
Enrollment
320 (estimated)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

palmoplantar pustulosis